A review of the study of the effectiveness of drug candidate BGP-15 in delaying diastolic dysfunction in the Goto-Kakizaki rat model of diabetic cardiomyopathy

A tétel rövid nézete
dc.contributor.advisorJuhász, Béla
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorHollos, Nora
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentKurucz, Andrea
dc.contributor.opponentFehér, Pálma
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Kardiológiai Intézet::Kardiológiai Klinikahu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Gyógyszerésztudományi Kar::Gyógyszertechnológiai Tanszékhu_HU
dc.date.accessioned2021-06-17T10:47:11Z
dc.date.available2021-06-17T10:47:11Z
dc.date.created2020
dc.description.abstractReview of a current study to compare the drug candidate, BGP-15, to metformin and pioglitazone. The aim was to observe whether BGP-15 had any cardiovascular effects on Goto-Kakizaki (GotoK) rats. The reason for this is to find an alternative, enhanced treatment for diabetic cardiomyopathy that has a better side effect profile and is more effective than current antidiabetic medication. In the study, BGP-15 was found to restore diastolic function in GotoK rats. Metformin and pioglitazone had no significant effect on echocardiographic parameters.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent40hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/311250
dc.language.isoenhu_HU
dc.subjectBGP-15hu_HU
dc.subjectDiastolic dysfunctionhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológiahu_HU
dc.titleA review of the study of the effectiveness of drug candidate BGP-15 in delaying diastolic dysfunction in the Goto-Kakizaki rat model of diabetic cardiomyopathyhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)